High-level marketing copy about this area that is understandable by users who aren’t scientists / are from the general public. Example from Salk - One thing’s for certain: we get older. But the biology of aging is still largely a mystery. As for getting sick as we age - we think that might be optional. At Salk, we are dechiphering the molecular and cellular causes of aging, and searching for ways to stave off Alzheimer’s disease, diabetes, cancer, cardiovascular disease and other age-related ailments. We’re studying how the boyd heals itself, and we’re working on stem-cell technologies that may one day be used to replace organs damaged by injury and disease. They say aging isn’t for the timid, but we think bold science could help people stay healthy as they age.
Our researchers discovered a link between finasteride, a medication used to relieve urinary problems, and prevention of prostate cancer.
The Mays Cancer Center is a member of The Pediatric Oncology Experimental Therapeutics Investigators' Consortium (POETIC).
Home to the only National Cancer Institute-designated cancer center in South Texas, UT Health San Antonio MD Anderson Cancer Center conducts more than 200 clinical trials in over 30 types of cancers.

Help advance treatment as a healthy volunteer
Clinical trial participation is an invaluable way to contribute to the pursuit of new treatments for cancer-related diseases. Take action today; volunteer and play a role in finding a cure.
Additional highlights

A cornerstone of research-based medicine
The University of Texas Health Science Center at San Antonio broke ground and unveiled the cornerstone for the UT Health San Antonio Multispecialty and Research Hospital, a destination center for research and treatment of cancer and other complex diseases that disproportionately impact the people of South Texas.

UT Health San Antonio's Liu receives $100,000 grant from The Mary Kay Foundation
The Mary Kay Foundation on Oct. 22 announced that UT Health San Antonio is among its 2020 cancer grant recipients. The grants are awarded annually to top accredited research institutions in the United States conducting innovative translational research to better understand cancers that affect women.

Bladder cancer patients respond well to new immunotherapy tested at Mays Cancer Center
In patients with high-grade cancer in the lining of the bladder, cancer often comes back within a year following standard treatment.
Although there are several approved treatments, none have significantly improved survival with few side effects. However, a new study evaluating a novel immunotherapy called nadofaragene firadenovec (NF) gene therapy may offer new hope.